ECSP23070237A - Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof - Google Patents

Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof

Info

Publication number
ECSP23070237A
ECSP23070237A ECSENADI202370237A ECDI202370237A ECSP23070237A EC SP23070237 A ECSP23070237 A EC SP23070237A EC SENADI202370237 A ECSENADI202370237 A EC SENADI202370237A EC DI202370237 A ECDI202370237 A EC DI202370237A EC SP23070237 A ECSP23070237 A EC SP23070237A
Authority
EC
Ecuador
Prior art keywords
tl1a
compositions
tnf
ligand
humanized antibodies
Prior art date
Application number
ECSENADI202370237A
Other languages
English (en)
Inventor
Robert Payne
Olivier Laurent
Janine Bilsborough
Allison Luo
Mark Manning
Bradley Henkle
Stephan R Targan
Lauren Otsuki
Original Assignee
Prometheus Biosciences Inc
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometheus Biosciences Inc, Cedars Sinai Medical Center filed Critical Prometheus Biosciences Inc
Publication of ECSP23070237A publication Critical patent/ECSP23070237A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente documento, se describen anticuerpos humanizados anti-TL1A y composiciones farmacéuticas para el tratamiento de enfermedades inflamatorias intestinales (IBD), tales como la enfermedad de Crohn (CD) y colitis ulcerosa (UC).
ECSENADI202370237A 2021-02-18 2023-09-14 Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof ECSP23070237A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163150825P 2021-02-18 2021-02-18
US202163180892P 2021-04-28 2021-04-28
US202163226037P 2021-07-27 2021-07-27
US202163285781P 2021-12-03 2021-12-03

Publications (1)

Publication Number Publication Date
ECSP23070237A true ECSP23070237A (es) 2023-10-31

Family

ID=82931032

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202370237A ECSP23070237A (es) 2021-02-18 2023-09-14 Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof

Country Status (19)

Country Link
US (1) US20240309104A1 (es)
EP (1) EP4294444A4 (es)
JP (1) JP2024506940A (es)
KR (1) KR20230157973A (es)
AU (1) AU2022223420A1 (es)
BR (1) BR112023016672A2 (es)
CA (1) CA3207817A1 (es)
CL (1) CL2023002424A1 (es)
CO (1) CO2023011969A2 (es)
CR (1) CR20230436A (es)
DO (1) DOP2023000162A (es)
EC (1) ECSP23070237A (es)
GE (2) GEAP202416596A (es)
IL (1) IL305312A (es)
JO (1) JOP20230185A1 (es)
MX (1) MX2023009622A (es)
PE (1) PE20231681A1 (es)
TW (1) TW202246322A (es)
WO (1) WO2022178159A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230109779A (ko) 2013-03-27 2023-07-20 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
CN114375339A (zh) 2019-05-14 2022-04-19 普罗米修斯生物科学公司 Tl1a患者选择方法、系统和装置
CN114901311A (zh) 2019-10-24 2022-08-12 普罗米修斯生物科学公司 Tnf样配体1a（tl1a）的人源化抗体及其用途
WO2024137353A1 (en) * 2022-12-22 2024-06-27 Prometheus Biosciences, Inc. Methods of treating inflammatory diseases with combination of tl1a inhibitors and s1pr inhibitors
WO2024173838A2 (en) * 2023-02-17 2024-08-22 Prometheus Biosciences, Inc. Anti-tl1a antibody compositions and methods of treatment in the bile duct
IL325993A (en) 2023-08-11 2026-03-01 Paragon Therapeutics Inc TL1A binding proteins and methods of use
US12473370B2 (en) 2023-10-03 2025-11-18 Absci Corporation TL1A associated antibody compositions and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3375B1 (ar) * 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
EP3068801A1 (en) * 2013-11-13 2016-09-21 Pfizer Inc. Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
US10968279B2 (en) * 2016-05-09 2021-04-06 Bristol-Myers Squibb Company TL1A antibodies and uses thereof
CN118240830A (zh) * 2016-10-26 2024-06-25 西达-赛奈医疗中心 中和抗tl1a单克隆抗体
CN112585165B8 (zh) * 2018-04-25 2025-02-14 普罗米修斯生物科学公司 优化的抗tl1a抗体
WO2021081365A1 (en) * 2019-10-24 2021-04-29 Prometheus Biosciences, Inc. Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof

Also Published As

Publication number Publication date
GEAP202416596A (en) 2024-10-28
EP4294444A1 (en) 2023-12-27
BR112023016672A2 (pt) 2023-11-21
PE20231681A1 (es) 2023-10-19
AU2022223420A1 (en) 2023-09-21
US20240309104A1 (en) 2024-09-19
IL305312A (en) 2023-10-01
GEAP202316354A (en) 2023-12-25
MX2023009622A (es) 2023-08-28
TW202246322A (zh) 2022-12-01
JOP20230185A1 (ar) 2023-08-09
CR20230436A (es) 2023-11-01
KR20230157973A (ko) 2023-11-17
CL2023002424A1 (es) 2024-01-05
EP4294444A4 (en) 2025-04-16
CO2023011969A2 (es) 2023-09-29
JP2024506940A (ja) 2024-02-15
WO2022178159A1 (en) 2022-08-25
CA3207817A1 (en) 2022-08-25
DOP2023000162A (es) 2023-10-15

Similar Documents

Publication Publication Date Title
CR20230436A (es) Composiciones que comprenden anticuerpos humanizados contra ligandos de tipo tnf 1a (tl1a) y sus usos
ZA202204557B (en) Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
CL2022001016A1 (es) Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos
ECSP23070234A (es) Anti-cd30l antibodies and uses thereof
MY191324A (en) Neutralizing anti-tl1a monoclonal antibodies
UY33715A (es) Anticuerpos humanos contra el ligando 1a de tipo tnf humano (tl1a)
HRP20201600T1 (hr) Anti-pd-1 antitijelo i njegova uporaba
ECSP15038626A (es) A61k 30/395
BR112014021251A2 (pt) anticorpos humanos para toxinas de clostridium difficile
CL2024003618A1 (es) Proteína de unión a antígeno aislada que se une a trem-1 humano.
MX2019007404A (es) Moleculas de union a adam9 y metodos de uso de las mismas.
BR112019005456A2 (pt) composição farmacêutica e método para tratamento de esteatose hepática não alcoólica
MX2025001038A (es) Anticuerpos anti-cd30l, formulaciones de estos, y uso de los mismos
MX379140B (es) Sal de etano-sulfonato del derivado de quinolina.
BR112022019958A2 (pt) Composições e métodos para o tratamento de doenças inflamatórias do intestino utilizando anticorpos inibidores de ccr9 e anticorpos de bloqueio anti-il -23
DOP2023000160A (es) Anticuerpos anti-cd30l y usos de estos
RU2013155270A (ru) Инденовые производные для применения в лечении воспалительного заболевания кишечника
AR111845A1 (es) Anticuerpos biespecíficos anti-cgrp / anti-il-23 y usos de los mismos
AR133812A1 (es) INHIBICIÓN DE LA INTEGRINA a4b7 HUMANA
CO2026003130A2 (es) Inhibición de la integrina α4β7 humana
EA202191738A1 (ru) Соединения имидазопиридазина и имидазопиридина и их применение
EA201992625A1 (ru) Способы и композиции для лечения воспалительных расстройств желудочно-кишечного тракта
EA201992378A1 (ru) Белки для лечения дисфункций эпителиального барьера
CL2008003236A1 (es) Compuestos derivados de pirimidinas 2,4,6-trisustituidas; cosicion farmaceutica que los comprende; y su uso en el tratamiento y prevencion de enfermedades relacionadas con el sistema inmune, tales como rechazo al traplante, artritis reumatoide, esclerosis multiple, enfermedad de crohn, colitis ulcerosa, psoriasis, entre otras.
TH169351A (th) สารประกอบไตรไซคลิกที่เป็นตัวยับยั้งการกดภูมิคุ้มกัน โดยอาศัยทริปโตแฟนเมแทบอไลเซชันเป็นสื่อกลาง